Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10490002 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| Ethylene Glycol SCHEMBL3625093 | 0.97 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| Sulfuric Acid SCHEMBL7496979 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FNTA | |
| Sulfuric Acid SCHEMBL7504984 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL26945939 | 0.92 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL6064367 | 0.92 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL19293541 | 0.92 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL6658547 | 0.91 | PTGS1 (0.57) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL24359832 | 0.90 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL14842415 | 0.90 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1471903-B1 | USE OF GLUTATHIONE SYNTHESIS STIMULATING COMPOUNDS IN REDUCING INSULIN RESISTANCE | SCIMAR LTD (CA) | 2019-11-20 | — | — | EP | claimed |
| US-20170002393-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC. (US) | 2017-01-05 | — | — | US | claimed |
| EP-3077522-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | Immunogen, Inc. (US) | 2016-10-12 | — | — | EP | claimed |
| WO-2015085003-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC. (US) | 2015-06-11 | — | — | WO | claimed |
| US-7622447-B2 | Use of glutathione synthesis stimulating compounds in reducing insulin resistance | DIAMEDICA INC. (CA) | 2009-11-24 | — | — | US | claimed |
| US-20090233995-A1 | Use of drug combinations for treating insulin resistance | DIAMEDICA INC. (CA) | 2009-09-17 | — | — | US | claimed |
| EP-1758597-A4 | USE OF DRUG COMBINATIONS FOR TREATING INSULIN RESISTANCE | DIAMEDICA INC (CA) | 2008-02-27 | — | — | EP | claimed |
| US-20070238762-A1 | Use of Antagonists of Hepatic Sympathetic Nerve Activity | DIAMEDICA INC. (CA) | 2007-10-11 | — | — | US | claimed |
| WO-2007082381-A1 | COMPOSITIONS CONTAINING (S)-BETHANECHOL AND THEIR USE IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, GLUCOSE INTOLERANCE AND RELATED DISORDERS | DIAMEDICA INC. (CA) | 2007-07-26 | — | — | WO | claimed |
| EP-1758597-A1 | USE OF DRUG COMBINATIONS FOR TREATING INSULIN RESISTANCE | Diamedica Inc. (CA) | 2007-03-07 | — | — | EP | claimed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | claimed |
| US-5686436-A | SUPPRESSING HUMAN IMMUNODEFICIENCY VIRUS, FELINE IMMUNODEFICIENCY VIRUS, FELINE LEUKEMIA VIRUS | HIV DIAGNOSTICS, INC. (US) | 1997-11-11 | — | — | US | claimed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| EP-0647444-A1 | L-2-oxothiazolidine-4-carboxylate and other stimulators of intracellular glutathione synthesis for reducing or preventing bone marrow hypoplasia | Transcend Therapeutics, Inc. (US) | 1995-04-12 | — | — | EP | claimed |
| EP-0624368-A2 | Use of a composition for stimulating the synthesis of glutathione in the manufacture of a medicament for the treatment of acquired immune deficiency syndrome | Transcend Therapeutics, Inc. (US) | 1994-11-17 | — | — | EP | claimed |
| WO-1994017799-A1 | METHOD FOR TREATING INFERTILITY | FREE RADICAL SCIENCES, INC. (US) | 1994-08-18 | — | — | WO | claimed |
| EP-0572110-A2 | Method of reducing or preventing toxicity associated with antiretroviral therapy by stimulation of the intracellular gluthatione level | Transcend Therapeutics, Inc. (US) | 1993-12-01 | — | — | EP | claimed |
| EP-0501641-A1 | L-2-oxothiazolidine-4-carboxylate and glutathion esters for the treatment of hepatic diseases | CLINTEC NUTRITION COMPANY (US) | 1992-09-02 | — | — | EP | claimed |
| EP-0494405-A2 | Use of thiazolidine-4-carboxylate derivatives for the treatment of pulmonary diseases | Transcend Therapeutics, Inc. (US) | 1992-07-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002393-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | TXNRD1, P4HB, CYBB | PTGS1 1016/4885GSTK1 270/4885GLO1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.